Connection

Mark Kindy to Cathepsin B

This is a "connection" page, showing publications Mark Kindy has written about Cathepsin B.
Connection Strength

2.571
  1. The cysteine protease cathepsin B is a key drug target and cysteine protease inhibitors are potential therapeutics for traumatic brain injury. J Neurotrauma. 2014 Mar 01; 31(5):515-29.
    View in: PubMed
    Score: 0.433
  2. Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing A?PP containing the wild-type ?-secretase site sequence. J Alzheimers Dis. 2012; 29(4):827-40.
    View in: PubMed
    Score: 0.375
  3. The cysteine protease inhibitor, E64d, reduces brain amyloid-? and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, ?-secretase activity. J Alzheimers Dis. 2011; 26(2):387-408.
    View in: PubMed
    Score: 0.349
  4. Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease. Biol Chem. 2010 Aug; 391(8):861-72.
    View in: PubMed
    Score: 0.339
  5. Cysteine protease inhibitors reduce brain beta-amyloid and beta-secretase activity in vivo and are potential Alzheimer's disease therapeutics. Biol Chem. 2007 Sep; 388(9):979-83.
    View in: PubMed
    Score: 0.277
  6. Cathepsin B Gene Knockout Improves Behavioral Deficits and Reduces Pathology in Models of Neurologic Disorders. Pharmacol Rev. 2022 07; 74(3):600-629.
    View in: PubMed
    Score: 0.194
  7. GM6 Attenuates Alzheimer's Disease Pathology in APP Mice. Mol Neurobiol. 2019 Sep; 56(9):6386-6396.
    View in: PubMed
    Score: 0.154
  8. Reduced Neuroinflammation and Improved Functional Recovery after Traumatic Brain Injury by Prophylactic Diet Supplementation in Mice. Nutrients. 2019 01 31; 11(2).
    View in: PubMed
    Score: 0.153
  9. Brain pyroglutamate amyloid-? is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic. J Alzheimers Dis. 2014; 41(1):129-49.
    View in: PubMed
    Score: 0.108
  10. Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein. Biochem Biophys Res Commun. 2009 Aug 21; 386(2):284-8.
    View in: PubMed
    Score: 0.078
  11. Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein. J Biol Chem. 2008 Mar 21; 283(12):7745-53.
    View in: PubMed
    Score: 0.071
  12. Cysteine Cathepsins in the secretory vesicle produce active peptides: Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's disease. Biochim Biophys Acta. 2012 Jan; 1824(1):89-104.
    View in: PubMed
    Score: 0.023
  13. Cysteine protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's disease. Biol Chem. 2007 Feb; 388(2):247-52.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.